Clearside Income Before Tax vs Ebitda Analysis
CLSD Stock | USD 1.08 0.06 5.88% |
Clearside Biomedical financial indicator trend analysis is way more than just evaluating Clearside Biomedical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Clearside Biomedical is a good investment. Please check the relationship between Clearside Biomedical Income Before Tax and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.
Income Before Tax vs Ebitda
Income Before Tax vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Clearside Biomedical Income Before Tax account and Ebitda. At this time, the significance of the direction appears to have totally related.
The correlation between Clearside Biomedical's Income Before Tax and Ebitda is 0.99. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Ebitda in the same time period over historical financial statements of Clearside Biomedical, assuming nothing else is changed. The correlation between historical values of Clearside Biomedical's Income Before Tax and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Clearside Biomedical are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Income Before Tax i.e., Clearside Biomedical's Income Before Tax and Ebitda go up and down completely randomly.
Correlation Coefficient | 0.99 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Clearside Biomedical income statement and is an important metric when analyzing Clearside Biomedical profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Ebitda
Most indicators from Clearside Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Clearside Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.The current year's Selling General Administrative is expected to grow to about 12.1 M, whereas Issuance Of Capital Stock is forecasted to decline to about 1.6 M.
Clearside Biomedical fundamental ratios Correlations
Click cells to compare fundamentals
Clearside Biomedical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Clearside Biomedical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 26.8M | 19.3M | 42.9M | 51.3M | 34.0M | 37.7M | |
Short Long Term Debt Total | 6.4M | 2.0M | 675K | 1.3M | 43.0M | 45.2M | |
Other Current Liab | 2.9M | 1.2M | 2.9M | 3.8M | 3.8M | 2.6M | |
Total Current Liabilities | 10.9M | 9.9M | 4.6M | 5.8M | 6.8M | 7.6M | |
Total Stockholder Equity | 11.2M | 8.8M | 38.0M | 10.6M | (15.9M) | (15.1M) | |
Property Plant And Equipment Net | 1.2M | 944K | 607K | 1.9M | 3.9M | 4.1M | |
Net Debt | (16.2M) | (15.3M) | (29.8M) | (47.0M) | 14.1M | 14.8M | |
Retained Earnings | (237.7M) | (255.9M) | (255.5M) | (288.4M) | (320.9M) | (304.9M) | |
Accounts Payable | 1.3M | 2.0M | 941K | 1.1M | 2.2M | 2.5M | |
Cash | 22.6M | 17.3M | 30.4M | 48.3M | 28.9M | 23.0M | |
Non Current Assets Total | 1.6M | 1.2M | 767K | 3.0M | 3.9M | 4.1M | |
Non Currrent Assets Other | 360K | 260K | 160K | 1.1M | 30K | 28.5K | |
Cash And Short Term Investments | 22.6M | 17.3M | 30.4M | 48.3M | 28.9M | 34.0M | |
Common Stock Total Equity | 44K | 52K | 60K | 61K | 70.2K | 73.7K | |
Common Stock Shares Outstanding | 38.2M | 46.5M | 59.9M | 60.2M | 61.8M | 37.3M | |
Liabilities And Stockholders Equity | 26.8M | 19.3M | 42.9M | 51.3M | 34.0M | 37.7M | |
Non Current Liabilities Total | 4.7M | 616K | 288K | 34.0M | 43.1M | 45.3M | |
Other Current Assets | 1.5M | 831K | 1.7M | 1.1M | 1.0M | 670.7K | |
Other Stockholder Equity | 248.8M | 264.6M | 293.4M | 299.0M | 304.9M | 184.5M | |
Total Liab | 15.6M | 10.6M | 4.9M | 40.7M | 49.9M | 27.5M | |
Property Plant And Equipment Gross | 1.2M | 944K | 1.6M | 2.7M | 4.8M | 5.0M | |
Total Current Assets | 25.2M | 18.1M | 42.1M | 48.3M | 30.1M | 35.9M | |
Common Stock | 44K | 52K | 60K | 61K | 63K | 37.2K | |
Other Liab | 605K | 10.5M | 4.6M | 34.0M | 39.1M | 41.0M | |
Net Tangible Assets | 11.2M | 8.8M | 38.0M | 10.6M | 12.2M | 15.8M | |
Other Assets | 360K | 260K | 160K | 30K | 1.0 | 0.95 | |
Short Long Term Debt | 3.2M | 556K | 1.3M | 991K | 891.9K | 847.3K | |
Short Term Debt | 1.7M | 1.7M | 774K | 698K | 728K | 1.2M | |
Property Plant Equipment | 1.2M | 944K | 238K | 755K | 868.3K | 643.4K | |
Capital Surpluse | 248.8M | 264.6M | 293.4M | 299.0M | 343.8M | 222.9M | |
Retained Earnings Total Equity | (237.7M) | (255.9M) | (255.5M) | (288.4M) | (259.6M) | (272.6M) | |
Net Invested Capital | 16.3M | 9.8M | 38.0M | 10.6M | (15.9M) | (15.1M) | |
Net Working Capital | 14.3M | 8.2M | 37.5M | 43.6M | 23.3M | 29.1M | |
Capital Stock | 44K | 52K | 60K | 61K | 63K | 57.2K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.